| Not Yet Recruiting | Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis NCT07367932 | Cairo University | Phase 4 |
| Recruiting | A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis NCT07230860 | Janssen Research & Development, LLC | Phase 2 |
| Recruiting | Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had I NCT06899204 | Pfizer | — |
| Recruiting | Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis NCT07042126 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 |
| Active Not Recruiting | A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) NCT06881251 | Janssen Research & Development, LLC | Phase 2 |
| Active Not Recruiting | A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in NCT06790121 | Sanofi | Phase 2 |
| Completed | An Observational Study to Gather Real-World User Feedback on DIPROBASE® Advanced Eczema Cream in Adults and Ch NCT06747897 | Bayer | — |
| Active Not Recruiting | An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Subst NCT06686628 | Sanofi | Phase 1 |
| Active Not Recruiting | Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic De NCT06554847 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 |
| Active Not Recruiting | Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis NCT06324812 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis NCT06526182 | Almirall, S.A. | Phase 3 |
| Recruiting | Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry) NCT06353087 | Pfizer | — |
| Terminated | Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. NCT06447506 | GlaxoSmithKline | Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compare NCT06407934 | Sanofi | Phase 3 |
| Completed | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With NCT06248814 | Bristol-Myers Squibb | Phase 1 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids NCT06241118 | Sanofi | Phase 3 |
| Active Not Recruiting | A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermat NCT05983068 | Sanofi | Phase 4 |
| Completed | Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese NCT06173284 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Olde NCT06224348 | Sanofi | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in P NCT06181435 | Sanofi | Phase 3 |
| Recruiting | A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions ( NCT06192563 | Sanofi | — |
| Terminated | A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Mode NCT05999799 | GlaxoSmithKline | Phase 2 |
| Active Not Recruiting | Evaluate the Safety, Tolerability of BAT6026 NCT06094179 | Bio-Thera Solutions | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in P NCT06130566 | Sanofi | Phase 3 |
| Recruiting | The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis NCT06488742 | Nexgen Dermatologics, Inc. | N/A |
| Completed | A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Ag NCT06015308 | Sanofi | Phase 2 |
| Completed | Emollient 'Plus' vs Urea 10% for Mild-Moderate Atopic Dermatitis NCT06553417 | Dr. Soetomo General Hospital | N/A |
| Completed | A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatiti NCT05870865 | Formation Bio, Inc. | Phase 2 |
| Recruiting | Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 NCT05769777 | Sanofi | Phase 2 |
| Recruiting | A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis NCT05391061 | Pfizer | — |
| Completed | Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China NCT05624112 | Sanofi | Phase 4 |
| Completed | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a S NCT05590338 | GlaxoSmithKline | Phase 1 |
| Completed | Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis NCT05544591 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 |
| Completed | Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease NCT05177744 | Children's Hospital Srebrnjak | — |
| Enrolling By Invitation | Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Se NCT05492578 | Sanofi | Phase 2 / Phase 3 |
| Terminated | A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis NCT05486208 | Eli Lilly and Company | Phase 1 |
| Completed | Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008) NCT05450198 | Merck Sharp & Dohme LLC | Phase 1 |
| Terminated | A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis NCT05250115 | Pfizer | — |
| Terminated | Assessment of Clinical, Biological and Biometrological Paramaters in Adult Subjects Suffering From AD NCT05639738 | Pierre Fabre Dermo Cosmetique | N/A |
| Completed | A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Sk NCT05226143 | Johnson & Johnson Consumer Inc. (J&JCI) | N/A |
| Completed | A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quant NCT05235724 | Sanofi | — |
| Completed | A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants NCT05214326 | Sanofi | — |
| Completed | A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) Th NCT05149313 | Almirall, S.A. | Phase 3 |
| Completed | Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis NCT04975438 | GlaxoSmithKline | Phase 1 |
| Completed | A Study of a Polymeric Surfactant Technology Cleanser in Sensitive Skin Participants NCT05094700 | Johnson & Johnson Consumer Inc. (J&JCI) | N/A |
| Completed | Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis NCT05641558 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis NCT04990440 | Janssen Research & Development, LLC | Phase 2 |
| Unknown | Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis NCT04761978 | University Hospital, Lille | — |
| Unknown | Integrative Body-Mind-Spirit Intervention for Families With Children Suffering From Eczema NCT04617977 | The University of Hong Kong | N/A |
| Completed | A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis NCT05014438 | Bristol-Myers Squibb | Phase 2 |
| Unknown | NMF-CsA-Dupi Trial NCT04878770 | Erasmus Medical Center | N/A |
| Unknown | Results in Real Clinical Practice of Treatment of Moderate-severe Atopic Dermatitis NCT05078294 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | — |
| Completed | To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis NCT04684485 | Sun Pharmaceutical Industries Limited | Phase 2 |
| Unknown | China Atopic Dermatitis Registry Study NCT05023668 | Peking University People's Hospital | — |
| Unknown | Safety and Efficacy of FURESTEM-AD Inj. for Moderate to Severe Atopic Dermatitis (AD) NCT05004324 | Kang Stem Biotech Co., Ltd. | Phase 3 |
| Completed | A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe NCT04800315 | Celgene | Phase 2 |
| Terminated | A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatiti NCT04791319 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis NCT04823130 | Sanofi | Phase 4 |
| Completed | A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With NCT04760314 | Eli Lilly and Company | Phase 3 |
| Completed | Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis NCT04718870 | Sanofi | Phase 4 |
| Completed | A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infan NCT04740892 | Johnson & Johnson Consumer Inc. (J&JCI) | N/A |
| Active Not Recruiting | Goat Infant Formula Feeding and Eczema (the GIraFFE Study) NCT04599946 | Dairy Goat Co-operative (N.Z.) Limited | N/A |
| Terminated | A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD) NCT04220411 | Arjil Pharmaceuticals LLC | Phase 1 / Phase 2 |
| Completed | Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis NCT04635072 | RCSI & UCD Malaysia Campus | EARLY_Phase 1 |
| Unknown | Long-Term Safety Follow-Up Study of SCM-AGH in Subjects Who Participated and Administered SCM-AGH in to Severe NCT04185584 | SCM Lifescience Co., LTD. | — |
| Withdrawn | Moisturizer to Prevent Atopic Dermatitis NCT03808532 | MYOR Ltd. | Phase 2 |
| Completed | Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermati NCT04440410 | Kymera Therapeutics, Inc. | — |
| Completed | Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis NCT04179760 | SCM Lifescience Co., LTD. | Phase 1 / Phase 2 |
| Completed | A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic D NCT04365387 | Galderma R&D | Phase 2 |
| Unknown | Study on the Correlation Between Intestinal Microecology and Allergic Diseases in Children NCT04938700 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 4 |
| Completed | A Study of LY3471851 in Participants With Eczema NCT04081350 | Nektar Therapeutics | Phase 1 |
| Completed | A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application NCT04135560 | Pfizer | Phase 1 |
| Terminated | A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0 NCT04086121 | Boehringer Ingelheim | Phase 2 |
| Completed | Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2) NCT04011215 | Murdoch Childrens Research Institute | N/A |
| Active Not Recruiting | Observational Evaluation of Atopic Dermatitis in Pediatric Patients NCT03687359 | Sanofi | — |
| Completed | Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formul NCT04065633 | Pfizer | Phase 1 |
| Active Not Recruiting | Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) NCT03992417 | Sanofi | — |
| Completed | Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis NCT03868098 | Innovaderm Research Inc. | Phase 4 |
| Active Not Recruiting | Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients (PEDISTAD BIOMARKER STUDY) NCT03849716 | Sanofi | — |
| Unknown | Study to Evaluate the Use of RHT-3201 in SCORAD Reduction in Young Patients With Atopic Dermatitis NCT03907228 | IlDong Pharmaceutical Co Ltd | N/A |
| Completed | Improving Therapeutic Patient Education for Atopic Dermatitis: Evaluation of a Parent Handbook NCT03722706 | Boston Children's Hospital | N/A |
| Completed | A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier NCT03901144 | ACO Hud Nordic AB | Phase 2 |
| Completed | A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated NCT03822832 | Boehringer Ingelheim | Phase 2 |
| Completed | Study to Evaluate ASN008 Topical Gel (TG) NCT03798561 | Asana BioSciences | Phase 1 |
| Recruiting | Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy NCT05674695 | Fundación Academia Española de Dermatología | — |
| Completed | A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis NCT03754309 | Kymab Limited | Phase 2 |
| Completed | A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis NCT03750643 | Eli Lilly and Company | Phase 1 |
| Completed | Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe At NCT03720470 | Pfizer | Phase 3 |
| Completed | Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis NCT03568136 | GWT-TUD GmbH | Phase 2 |
| Completed | Functional Study to Investigate the Efficacy of a New Medical Device (Modified Diprobase Formulation) NCT03672383 | Bayer | N/A |
| Completed | Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-0496584 NCT03634345 | Pfizer | Phase 1 |
| Completed | Effect of Benralizumab in Atopic Dermatitis NCT03563066 | McMaster University | Phase 2 |
| Completed | Effect of Different Skin Creams on TEWL NCT03663673 | Stanford University | Phase 1 |
| Completed | Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Sever NCT03575871 | Pfizer | Phase 3 |
| Completed | Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Se NCT03627767 | Pfizer | Phase 3 |
| Active Not Recruiting | Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) NCT03428646 | Regeneron Pharmaceuticals | — |
| Completed | Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Y NCT03422822 | Pfizer | Phase 3 |
| Unknown | Efficacy Of Antenatal Maternal Supplementation With GOS/Inulin Prebiotics On Atopic Dermatitis Prevalence In H NCT03183440 | Nantes University Hospital | N/A |
| Completed | Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Seve NCT03349060 | Pfizer | Phase 3 |
| Completed | Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe A NCT03346434 | Regeneron Pharmaceuticals | Phase 2 / Phase 3 |
| Completed | Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in P NCT03345914 | Regeneron Pharmaceuticals | Phase 3 |
| Completed | Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis NCT03233529 | Pfizer | Phase 2 |
| Completed | Topical NanoDox® for Atopic Dermatitis NCT02910011 | University of Florida | Phase 2 |
| Completed | A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis NCT03139981 | Asana BioSciences | Phase 1 |
| Completed | A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis NCT03096223 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Terminated | Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis NCT03055195 | GlaxoSmithKline | Phase 2 |
| Completed | Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Derma NCT03054428 | Regeneron Pharmaceuticals | Phase 3 |
| Completed | Treatment of Atopic Dermatitis by a Full-Body Blue Light Device NCT03085303 | Philips Electronics Nederland BV | N/A |
| Completed | In-Use Test With a Cosmetic Product NCT03252730 | Dr. August Wolff GmbH & Co. KG Arzneimittel | N/A |
| Unknown | Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis: Randomized, Double-blind Controlled T NCT03042624 | University of Milan | N/A |
| Completed | Atopic Dermatitis in Atopy Predisposed Infants NCT02906475 | HiPP GmbH & Co. Vertrieb KG | N/A |
| Completed | Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients NCT02900131 | Kyung Hee University Hospital at Gangdong | Phase 2 |
| Completed | A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Spec NCT02916888 | Yale University | — |
| Completed | Animal Allergy in Korean Veterinary Researcher NCT02866864 | Gachon University Gil Medical Center | — |
| Completed | First in Human of Single and Multiple Doses of MOR106 NCT02739009 | Galapagos NV | Phase 1 |
| Completed | Topical Steroid Formulation and Wet Wraps NCT02680301 | Seton Healthcare Family | Phase 4 |
| Completed | Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis NCT02732314 | Procter & Gamble Beauty | Phase 4 |
| Terminated | Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients NCT02713035 | University of Mississippi Medical Center | N/A |
| Completed | Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis NCT03059693 | Haus Bioceuticals | Phase 1 / Phase 2 |
| Terminated | A Multicenter Randomized Control Trial in Children With Moderate to Severe Atopic Dermatitis to Assess the Ben NCT02634905 | Nantes University Hospital | N/A |
| Completed | Intervention Study to Evaluate a Probiotic in Mild Atopic Dermatitis Young Patients NCT02585986 | Biopolis S.L. | N/A |
| Completed | Curing Atopic Dermatits in Children With a Commerical Medical Device and Maintaining Healthy Skin by Using a N NCT02615561 | Bayer | N/A |
| Completed | An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis NCT02655679 | Vitae Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switche NCT02627989 | LEO Pharma | — |
| Completed | A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD) NCT02564055 | GlaxoSmithKline | Phase 2 |
| Completed | Skin Irritation Study of GSK2894512 Cream NCT02637206 | GlaxoSmithKline | Phase 1 |
| Completed | A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects NCT02590289 | Fresh Tracks Therapeutics, Inc. | Phase 1 |
| Terminated | Bathing Additives in Pediatric Atopic Dermatitis NCT02582788 | Mayo Clinic | N/A |
| Completed | Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic De NCT02595008 | Sun Pharmaceutical Industries, Inc. | Phase 2 |
| Completed | Does Treatment With Montelukast Improve Symptoms of Atopic Dermatitis in Children? NCT02534467 | Murdoch Childrens Research Institute | Phase 4 |
| Completed | A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream NCT02411162 | Stiefel, a GSK Company | Phase 1 |
| Completed | Pharmacokinetic Study of Topical GSK2894512 Cream NCT02466152 | GlaxoSmithKline | Phase 1 |
| Completed | Study of Autologous Total Immunoglobulin G Therapy for Atopic Dermatitis NCT02835170 | Ajou University School of Medicine | Phase 2 / Phase 3 |
| Completed | The Effectiveness of Tailored Messages on the Usage of Emollient in Patients With Atopic Dermatitis NCT02343861 | Seoul National University Hospital | N/A |
| Completed | A Study to Evaluate Use of Induced Skin Blisters in Adult Participants With Atopic Dermatitis, Allergic Asthma NCT02343783 | Janssen Research & Development, LLC | EARLY_Phase 1 |
| Terminated | A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and F NCT02317276 | University of California, San Francisco | Phase 4 |
| Completed | Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atop NCT02277769 | Regeneron Pharmaceuticals | Phase 3 |
| Unknown | Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis NCT02286700 | NeoStrata Company, Inc. | Phase 3 |
| Completed | Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis NCT02277743 | Regeneron Pharmaceuticals | Phase 3 |
| Completed | Wool Clothing for the Management of Childhood Atopic Dermatitis NCT02534428 | Murdoch Childrens Research Institute | N/A |
| Completed | ADRN Barrier/Immunoprofiling Exploratory Pilot Study NCT02115399 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Olde NCT02118792 | Pfizer | Phase 3 |
| Completed | Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients NCT02576093 | Dr. August Wolff GmbH & Co. KG Arzneimittel | Phase 1 |
| Completed | Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Olde NCT02118766 | Pfizer | Phase 3 |
| Completed | Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema) NCT02001181 | Pfizer | Phase 2 |
| Withdrawn | Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis NCT01691209 | Bayer | N/A |
| Completed | Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis NCT01948869 | Bayer | N/A |
| Completed | A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis NCT01945086 | Janssen Pharmaceutical K.K. | Phase 2 |
| Completed | Place of Flixovate® in the Treatment Pathway and Its Conditions of Use in Infants Aged From 3 to 12 Months Bet NCT01920464 | GlaxoSmithKline | — |
| Completed | The Effect of Bathing and Moisturizers on Skin Hydration in Atopic Dermatitis: an in Vivo Study NCT02028546 | Srinakharinwirot University | N/A |
| Completed | Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study NCT01737710 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Recruiting | Effects of Treatments on Atopic Dermatitis NCT01631617 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 |
| Completed | Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis NCT01602341 | Pfizer | Phase 2 |
| Completed | Investigation of Topical SB705498 on Healthy Volunteers NCT01673529 | GlaxoSmithKline | Phase 1 |
| Completed | Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis NCT01652885 | Pfizer | Phase 1 / Phase 2 |
| Terminated | A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis NCT01497119 | Janssen Pharmaceutical K.K. | Phase 2 |
| Unknown | Systemic Therapies for Pediatric Atopic Dermatitis NCT01447381 | Rady Children's Hospital, San Diego | — |
| Completed | Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis NCT01301508 | Pfizer | Phase 2 |
| Completed | A Study Assessing GW870086's Potential to Cause Skin Thinning NCT01381445 | GlaxoSmithKline | Phase 1 |
| Completed | Effect of Dietary Phospholipids on Atopic Dermatitis NCT01326520 | University of Jena | N/A |
| Completed | A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Pos NCT01299610 | GlaxoSmithKline | Phase 2 |
| Unknown | Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Corti NCT01011621 | Mantecorp Industria Quimica e Farmaceutica Ltd. | Phase 3 |
| Completed | Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the NCT01063218 | Galderma Brasil Ltda. | Phase 4 |
| Terminated | Efficacy Study of Topical Twice Weekly Fluticasone Treatment to Reduce Relapse in Atopic Dermatitis in Childre NCT01772056 | Elena Rubio Gomis | Phase 3 |
| Completed | Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream NCT01098734 | Welichem Biotech Inc. | Phase 2 |
| Terminated | Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4) NCT00671528 | Organon and Co | Phase 4 |
| Completed | Effect of Moisturising Creams on Skin Moisture in Atopic Dermatitis NCT00846235 | Orion Corporation, Orion Pharma | Phase 4 |
| Completed | Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatit NCT00673725 | Astellas Pharma Europe B.V. | Phase 4 |
| Completed | Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis NCT00837551 | Welichem Biotech Inc. | Phase 1 / Phase 2 |
| Completed | An Efficacy and Safety Study of Tacrolimus Ointment in Pediatric Participants With Atopic Dermatitis NCT01782729 | Janssen-Cilag Ltd.,Thailand | Phase 4 |
| Completed | Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Level NCT00616096 | University of Luebeck | N/A |
| Completed | An Efficacy and Safety Study of Tacrolimus Ointment in Adult Participants With Atopic Dermatitis NCT01828879 | Janssen-Cilag Ltd.,Thailand | Phase 4 |
| Completed | A Long-Term Examination of Asthma From Childhood Through Adolescence NCT00541255 | Isle of Wight NHS Trust | — |
| Completed | Topical GW842470X In Adults Patients With Moderate Atopic Dermatitis NCT00354510 | GlaxoSmithKline | Phase 2 |
| Completed | Immunopharmacological Effects of Rituximab in Atopic Dermatitis NCT00267826 | University of Bern | N/A |
| Completed | Study Of Atopic Dermatitis In Pediatrics NCT00257569 | GlaxoSmithKline | Phase 3 |
| Completed | Study Of Single And Ten Day Repeat Atopical Applications Of GW842470X Cream On The Skin Of Patients With Atopi NCT00356642 | GlaxoSmithKline | Phase 1 |
| Completed | Efalizumab for Moderate to Severe Atopic Dermatitis NCT00226057 | Oregon Health and Science University | Phase 1 |
| Completed | Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatiti NCT00121381 | Novartis | Phase 4 |
| Completed | Risk of Asthma in Infants With Atopic Dermatitis NCT00459576 | Indiana University School of Medicine | — |
| Completed | Efalizumab for Eczema NCT00146003 | University of Medicine and Dentistry of New Jersey | Phase 2 |
| Completed | Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis NCT00185510 | LEO Pharma | Phase 4 |
| Completed | A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis NCT00106496 | Astellas Pharma Inc | Phase 4 |
| Completed | Histamine Pharmacogenetics in Children With Atopic Dermatitis NCT00277433 | Virginia Commonwealth University | — |
| Completed | Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment NCT00480896 | Astellas Pharma Inc | Phase 3 |
| Completed | Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment NCT00480610 | Astellas Pharma Inc | Phase 3 |
| Completed | Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorder NCT00189917 | Bavarian Nordic | Phase 1 |
| Completed | Protopic Ointment in Adult Atopic Eczema of the Face NCT00690105 | Astellas Pharma Inc | Phase 4 |
| Completed | Protopic Ointment in Children Atopic Eczema NCT00689832 | Astellas Pharma Inc | Phase 4 |
| Completed | Clinical Trial to Assess the Efficacy and Safety of Tacrolimus Ointment Treatment of Atopic Dermatitis in Adul NCT00523952 | Astellas Pharma Inc | Phase 3 |
| Completed | Impact in Off-spring of Mothers After Perinatal Daily Intake of a Probiotic NCT00159523 | Norwegian University of Science and Technology | N/A |
| Completed | Study to Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus (FK506) Ointment Administered in Pe NCT00691262 | Astellas Pharma Inc | Phase 3 |
| Completed | Tacrolimus Ointment Long Term Safety in Young Children With Atopic Dermatitis NCT00560326 | Astellas Pharma Inc | Phase 2 |
| Completed | Tacrolimus Ointment Pharmacokinetics in Infants With Atopic Dermatitis NCT00535691 | Astellas Pharma Inc | Phase 2 |
| Completed | Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Allergic Skin Inflammat NCT00817076 | Organon and Co | Phase 3 |
| Completed | Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric NCT00666159 | Astellas Pharma Inc | Phase 4 |
| Completed | Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients NCT00667160 | Astellas Pharma Inc | Phase 4 |
| Completed | A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects NCT00666302 | Astellas Pharma Inc | Phase 4 |
| Completed | Study to Evaluate the Efficacy and Safety of 0.1% and 0.03% Tacrolimus Ointment Administered in Adults With Mo NCT00691145 | Astellas Pharma Inc | Phase 3 |
| Completed | Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema NCT00152464 | UCB Pharma SA | Phase 3 |
| Completed | WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients NCT02182557 | Boehringer Ingelheim | Phase 3 |
| Completed | WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients NCT02182570 | Boehringer Ingelheim | Phase 3 |
| Completed | Distribution of Tacrolimus in Skin, Atopic Dermatitis NCT00534508 | Astellas Pharma Inc | Phase 2 |
| Completed | Long-term Safety of Protopic in Atopic Eczema NCT00560378 | Astellas Pharma Inc | Phase 3 |